Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: VIUSID/ALZER
- Registration Number
- NCT01016470
- Lead Sponsor
- Catalysis SL
- Brief Summary
The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).
- Detailed Description
Periodical measures of the clinical features with UPDRS will be done at the beginning, each three months until two years. Each group will be compare to evaluate.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients with clinical of PD, with the criteria of Brain Bank of London with early stage.
- Informed consent.
Exclusion Criteria
- Presence of another disease not well controlled.
- Patient with atypical features.
- Patient with advanced Parkinson's disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description B Placebo Placebo A VIUSID/ALZER VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
- Primary Outcome Measures
Name Time Method Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment) one year
- Secondary Outcome Measures
Name Time Method Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment) one year Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment) one year
Trial Locations
- Locations (1)
"Salvador Allende Hospital"
🇨🇺Havana City, Havana, Cuba